Natalizumab (Tysarbi)

Tysabri (natalizumab) is covered for relapsing multiple sclerosis and moderately- to severely‑active Crohn’s disease with inflammation, but is contraindicated/ excluded for patients with anti‑JCV antibodies and must not be used concomitantly with immunosuppressants or TNF‑inhibitors. Coverage requires age ≥18, TOUCH® program enrollment, MS use as monotherapy, for Crohn’s prior failure/intolerance of ≥2 conventional therapies plus ≥1 TNF‑inhibitor with a 12‑week induction and documented benefit/tapered steroids for reauthorization, plus ongoing safety monitoring (no jaundice/significant liver injury, no opportunistic infections, and immediate hold if PML is suspected).

"Multiple Sclerosis"

Sign up to see full coverage criteria, indications, and limitations.